Feifei Na1, Jingwen Wang, Cong Li, Lei Deng, Jianxin Xue, You Lu. 1. *Huaxi Student Society of Oncology Research (HASSOR), West China School of Medicine, Sichuan University, Chengdu, Sichuan, China; †Department of Thoracic Cancer, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China; and ‡West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Abstract
INTRODUCTION: The 2-[18F]-Fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) has become an imaging tool for clinical assessment of tumor, node, metastasis in non-small-cell lung cancer (NSCLC). Primary tumor maximum standardized uptake value (SUV(max)) on (18)F-FDG PET/CT before and after radiation therapy (RT) has been studied as a potential prognostic factor for NSCLC patients receiving radiotherapy. However, the sample sizes of most studies were small, and the results of the prediction value of SUV(max) remained undetermined, which lead us to perform a meta-analysis to improve the precision in estimating its effect. METHODS: We performed a meta-analysis of published literature for primary tumor SUV(max)-based biomarkers of the outcome of NSCLC receiving radiotherapy. The required data for estimation of individual hazard ratios (HRs) to compare patients with a low and a high SUV(max) were extracted from each publication. A combined HR was calculated by Stata statistical software (Version 11). All of the results were verified by two persons to ensure its accuracy. RESULTS: Thirteen studies were finally included into this meta-analysis; data are available in 13 studies for pre-RT primary tumor SUV(max) and in five studies for post-RT. For overall survival, the combined HR estimate was 1.05 (95% confidence interval [CI], 1.02-1.08) and 1.32 (95% CI, 1.15-1.51) for pre-RT SUV(max) and post-RT SUV(max), respectively; 1.26 (95% CI, 1.05-1.52) and 2.01 (95% CI, 1.16-3.46) for local control (LC). In stereotactic body radiotherapy (SBRT) group, HR for LC was 1.11 (95% CI, 1.06-1.18) and 2.19 (95% CI, 1.34-3.60) for pre-SBRT SUV(max) and post-SBRT SUV(max), respectively. CONCLUSION: Both pre-RT and post-RT primary tumor SUV(max) can predict the outcome of patients with NSCLC treated with radiotherapy. Patients with high levels of pre-RT SUV(max) seemed to have poorer overall survival and LC.
INTRODUCTION: The 2-[18F]-Fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) has become an imaging tool for clinical assessment of tumor, node, metastasis in non-small-cell lung cancer (NSCLC). Primary tumor maximum standardized uptake value (SUV(max)) on (18)F-FDG PET/CT before and after radiation therapy (RT) has been studied as a potential prognostic factor for NSCLCpatients receiving radiotherapy. However, the sample sizes of most studies were small, and the results of the prediction value of SUV(max) remained undetermined, which lead us to perform a meta-analysis to improve the precision in estimating its effect. METHODS: We performed a meta-analysis of published literature for primary tumor SUV(max)-based biomarkers of the outcome of NSCLC receiving radiotherapy. The required data for estimation of individual hazard ratios (HRs) to compare patients with a low and a high SUV(max) were extracted from each publication. A combined HR was calculated by Stata statistical software (Version 11). All of the results were verified by two persons to ensure its accuracy. RESULTS: Thirteen studies were finally included into this meta-analysis; data are available in 13 studies for pre-RT primary tumor SUV(max) and in five studies for post-RT. For overall survival, the combined HR estimate was 1.05 (95% confidence interval [CI], 1.02-1.08) and 1.32 (95% CI, 1.15-1.51) for pre-RT SUV(max) and post-RT SUV(max), respectively; 1.26 (95% CI, 1.05-1.52) and 2.01 (95% CI, 1.16-3.46) for local control (LC). In stereotactic body radiotherapy (SBRT) group, HR for LC was 1.11 (95% CI, 1.06-1.18) and 2.19 (95% CI, 1.34-3.60) for pre-SBRT SUV(max) and post-SBRT SUV(max), respectively. CONCLUSION: Both pre-RT and post-RT primary tumor SUV(max) can predict the outcome of patients with NSCLC treated with radiotherapy. Patients with high levels of pre-RT SUV(max) seemed to have poorer overall survival and LC.
Authors: Dirk Verellen; Mark De Ridder; Nadine Linthout; Koen Tournel; Guy Soete; Guy Storme Journal: Nat Rev Cancer Date: 2007-12 Impact factor: 60.716
Authors: Jose L Lopez Guerra; Gregory Gladish; Ritsuko Komaki; Daniel Gomez; Yan Zhuang; Zhongxing Liao Journal: J Nucl Med Date: 2012-01-12 Impact factor: 10.057
Authors: Gerben R Borst; José S A Belderbos; Ronald Boellaard; Emile F I Comans; Katrien De Jaeger; Adriaan A Lammertsma; Joos V Lebesque Journal: Eur J Cancer Date: 2005-07 Impact factor: 9.162
Authors: Katy Clarke; Mojgan Taremi; Max Dahele; Marc Freeman; Sharon Fung; Kevin Franks; Andrea Bezjak; Anthony Brade; John Cho; Andrew Hope; Alexander Sun Journal: Radiother Oncol Date: 2012-06-09 Impact factor: 6.280
Authors: Dong Soo Lee; Yeon Sil Kim; Ie Ryung Yoo; Young Nam Kang; Seoung Jun Kim; Jin Kyung Oh; Young Kyoon Kim; Young Pil Wang; Jae Gil Park; Jin-Hyoung Kang; Dae Hee Han; Myung Im Ahn; Kyo Young Lee Journal: Lung Cancer Date: 2013-02-08 Impact factor: 5.705
Authors: Joe Y Chang; Hui Liu; Peter Balter; Ritsuko Komaki; Zhongxing Liao; James Welsh; Reza J Mehran; Jack A Roth; Stephen G Swisher Journal: Radiat Oncol Date: 2012-09-10 Impact factor: 3.481
Authors: M Dosani; R Yang; M McLay; D Wilson; M Liu; C J Yong-Hing; J Hamm; C R Lund; R Olson; D Schellenberg Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677
Authors: Hyung-Jun Im; Meiyappan Solaiyappan; Inki Lee; Tyler Bradshaw; Najat C Daw; Fariba Navid; Barry L Shulkin; Steve Y Cho Journal: Am J Nucl Med Mol Imaging Date: 2018-12-20
Authors: Lotte Nygård; Marianne C Aznar; Barbara M Fischer; Gitte F Persson; Charlotte B Christensen; Flemming L Andersen; Mirjana Josipovic; Seppo W Langer; Andreas Kjær; Ivan R Vogelius; Søren M Bentzen Journal: Am J Nucl Med Mol Imaging Date: 2018-04-25